stockrow
Monday 9 November 2026
Export ALMR’s income statement to Excel — free account
Alamar Biosciences, Inc.
ALMRAlamar Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $74.2 million, up 195.2% from fiscal 2024.
- Revenue
- +68.5%
- EPS
- +72.0%
- Free cash flow
- +1.07%
Quarter to September 2026, against a year earlier
28.05
1.14
+4.24%
Follow ALMR
Alert me
| Dec '24 | Dec '25 | |
|---|---|---|
P/E ratio |
0.00 | 0.00 |
P/S ratio |
3.09 | 3.09 |
Altman Z″-Score (non-manufacturers) |
(1.80) | (2.67) |
P/FCF ratio |
0.00 | 0.00 |
Beneish M-Score |
— | (0.82) |
P/Operating CF |
(13.26) | (13.26) |
P/B ratio |
0.00 | 0.00 |
Price to Tangible BV |
0.00 | 0.00 |
EV/Sales |
3.21 | 3.21 |
EV/EBITDA |
0.00 | 0.00 |
EV/Operating CF |
(4.60) | (4.60) |
EV/FCF |
(4.22) | (4.22) |
Quick Ratio |
5.20 | 1.80 |
Current Ratio |
6.43 | 3.99 |
Net Debt/EBITDA |
1.65 | 0.74 |
Debt/Assets |
0.00% | 7.01% |
Debt/Equity |
0.00 | (0.06) |
Asset Turnover |
0.00 | 0.51 |
Operating CF/Net income |
1.19 | 1.80 |
Capex/Depreciation |
(2.13) | (1.37) |
Interest Coverage |
(23.85) | (78.14) |
| 0.00% | 20.40% | |
| 0.00% | (20.60%) | |
ROIC |
0.00% | 0.00% |
Return on Tangible Assets |
(47.39%) | (36.60%) |
Average Days of Receivables |
96.51 | 62.72 |
Research and Development Expense of Revenue |
156.05% | 50.49% |
Selling, General and Administrative Expense of Revenue |
75.34% | 47.93% |
Intangible Assets out of Total Assets |
0.01 | 0.01 |
Share Based Compensation of Revenue |
3.47% | 3.87% |
Graham Net Nets |
(0.83) | (0.83) |
Graham Number |
0.00 | 28.28 |
Earnings Yield |
(16.55%) | (16.55%) |
Free Cash Flow Yield |
(24.58%) | (24.58%) |
Revenue per Share |
2.39 | 6.43 |
Operating CF per Share |
(5.25) | (4.64) |
Capex per Share |
(0.28) | (0.47) |
Free Cash Flow per Share |
(5.53) | (5.11) |
Cash per Share |
7.57 | 2.60 |
Shareholders Equity per Share |
(12.68) | (13.76) |
Interest Debt per Share |
0.00 | 0.00 |
Book value per Share |
(12.68) | (13.76) |
Free Cash Flow |
(58.16) | (58.98) |
Working Capital |
90.11 | 70.98 |
Capital Expenditures |
(2.95) | (5.37) |
Net Current Asset Value |
(176.22) | (204.24) |
EV/EBIT |
0.00 | 0.00 |
Capex to Sales |
0.12 | 0.07 |
Price to Operating Income |
0.00 | 0.00 |
| Other line items | ||
Depreciation/Fixed assets |
0.18 | 0.37 |
Cash ROIC |
108.12% | 49.50% |
Accounts Receivable Turnover |
0.00 | 7.65 |
Accounts Payable Turnover |
0.00 | 5.39 |
Inventory Turnover |
0.00 | 1.23 |
Average Days of Payables |
136.57 | 65.93 |
Days of Inventory on Hand |
318.05 | 432.10 |
Average Receivables |
— | 9.70 |
Average Payables |
— | 6.03 |
Average Inventory |
— | 26.45 |
Average Assets |
— | 144.75 |
Average Common Equity |
— | (146.18) |
Columns are period end dates · fundamentals updated 6 Nov 2026